Positive Topline Results Announced in Type 1 Diabetes Clinical Trial

September 14, 2020

A clinical trial investigating a possible novel treatment of early-onset type 1 diabetes last month met the primary endpoint assessing the safety and tolerability of a new class of microbe-based therapeutic agents. Precigen ActoBio is evaluating this therapy — AG019 ActoBiotics — as a monotherapy and in combination with teplizumab. AG019 is formulated as an […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

←Endocrine Society, European Society of Endocrinology Partner to Produce Practice Protocols

Richard T. Kloos, MD, Named Executive Medical Director at Veracyte→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today